Abatacept for rheumatoid arthritis

Abatacept treatment for rheumatoid arthritis

“…This is supported by a recent Cochrane Review that reported the safety profile of abatacept to be acceptable [60]. …”

“…As with other biologics [60], abatacept demonstrates statistical significance in achieving clinical efficacy outcomes compared with placebo, over short-term, DB treatment at the group level. Furthermore, the clinical efficacy improvements seen with abatacept have been observed at the individual patient level, with post hoc analyses suggesting that patients responding to treatment had a high probability of maintaining or further improving responses over time.…”

Abatacept treatment for rheumatoid arthritis

“…This is supported by a recent Cochrane Review that reported the safety profile of abatacept to be acceptable [60]. …”

“…As with other biologics [60], abatacept demonstrates statistical significance in achieving clinical efficacy outcomes compared with placebo, over short-term, DB treatment at the group level. Furthermore, the clinical efficacy improvements seen with abatacept have been observed at the individual patient level, with post hoc analyses suggesting that patients responding to treatment had a high probability of maintaining or further improving responses over time.…”

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

“…A Cochrane review of randomised controlled trials in rheumatoid arthritis estimated a greater number of serious infections at 12 months of abatacept use compared to other disease‐modifying antirheumatic drugs (DMARDs) or biologics users (OR 1.91; 95% CI: 1.07‐3.42), while another systematic review and meta‐analysis in the same population calculated the incidence rate of serious infections in association with abatacept at 3.04 (95% CI: 2.49‐3.72)/100 patient‐years . A Cochrane review of randomised controlled trials of belatacept use in adult kidney transplant patients reported a risk ratio of serious infections with belatacept of 0.89 (95% CI: 0.73‐1.09) vs any other primary immunosuppression regimen …”

Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

“…Conventionally, biologics have been administered with methotrexate as a cotherapy, and therefore dissociating the specific effect of methotrexate in these trials is challenging. The overall clinical responses for each of these outcomes, collated from Cochrane and other systematic reviews, 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 are summarized in this section.…”

“… American College of Rheumatology (ACR) responses from Cochrane reviews of key clinical trials 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 …”

Abatacept treatment for rheumatoid arthritis

“…This is supported by a recent Cochrane Review that reported the safety profile of abatacept to be acceptable [60]. …”

“…As with other biologics [60], abatacept demonstrates statistical significance in achieving clinical efficacy outcomes compared with placebo, over short-term, DB treatment at the group level. Furthermore, the clinical efficacy improvements seen with abatacept have been observed at the individual patient level, with post hoc analyses suggesting that patients responding to treatment had a high probability of maintaining or further improving responses over time.…”

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

“…A Cochrane review of randomised controlled trials in rheumatoid arthritis estimated a greater number of serious infections at 12 months of abatacept use compared to other disease‐modifying antirheumatic drugs (DMARDs) or biologics users (OR 1.91; 95% CI: 1.07‐3.42), while another systematic review and meta‐analysis in the same population calculated the incidence rate of serious infections in association with abatacept at 3.04 (95% CI: 2.49‐3.72)/100 patient‐years . A Cochrane review of randomised controlled trials of belatacept use in adult kidney transplant patients reported a risk ratio of serious infections with belatacept of 0.89 (95% CI: 0.73‐1.09) vs any other primary immunosuppression regimen …”

Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

“…Conventionally, biologics have been administered with methotrexate as a cotherapy, and therefore dissociating the specific effect of methotrexate in these trials is challenging. The overall clinical responses for each of these outcomes, collated from Cochrane and other systematic reviews, 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 are summarized in this section.…”

“… American College of Rheumatology (ACR) responses from Cochrane reviews of key clinical trials 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 …”

Abatacept treatment for rheumatoid arthritis

“…This is supported by a recent Cochrane Review that reported the safety profile of abatacept to be acceptable [60]. …”

“…As with other biologics [60], abatacept demonstrates statistical significance in achieving clinical efficacy outcomes compared with placebo, over short-term, DB treatment at the group level. Furthermore, the clinical efficacy improvements seen with abatacept have been observed at the individual patient level, with post hoc analyses suggesting that patients responding to treatment had a high probability of maintaining or further improving responses over time.…”

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

“…A Cochrane review of randomised controlled trials in rheumatoid arthritis estimated a greater number of serious infections at 12 months of abatacept use compared to other disease‐modifying antirheumatic drugs (DMARDs) or biologics users (OR 1.91; 95% CI: 1.07‐3.42), while another systematic review and meta‐analysis in the same population calculated the incidence rate of serious infections in association with abatacept at 3.04 (95% CI: 2.49‐3.72)/100 patient‐years . A Cochrane review of randomised controlled trials of belatacept use in adult kidney transplant patients reported a risk ratio of serious infections with belatacept of 0.89 (95% CI: 0.73‐1.09) vs any other primary immunosuppression regimen …”

Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

“…Conventionally, biologics have been administered with methotrexate as a cotherapy, and therefore dissociating the specific effect of methotrexate in these trials is challenging. The overall clinical responses for each of these outcomes, collated from Cochrane and other systematic reviews, 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 are summarized in this section.…”

“… American College of Rheumatology (ACR) responses from Cochrane reviews of key clinical trials 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 …”